ZYDUS SEEKS DCGI NOD FOR TRIALS OF ANTIBODY COCKTAIL IN INDIA

Pharmaceutical major Zydus Cadila has sought national drugs controller’s permission to initiate phase 1/3 human clinical trials for its monoclonal antibodies to treat Covid-19, the company said on Thursday.

It is the only Indian company to have developed a neutralising monoclonal antibody-based cocktail for the treatment of Covid-19.

“At this juncture, there is a critical need to explore safer and more efficacious treatments to combat Covid. We believe that ZRC-3308 has the potential to address these concerns and provide a safe treatment,” said Sharvil Patel, managing director, Cadila Healthcare Ltd. Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses. NEW DELHI: